In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coherus BioSciences, Inc.

Latest From Coherus BioSciences, Inc.

Coherus Positive And Up For The Fight Amid Amneal Pegfilgrastim Deals

Coherus BioSciences feels its bearing and clout in the US pegfilgrastim market will stand it in good stead as other players scrabble to compete on the more lucrative formulations of Amgen’s Neulasta.

Sales & Earnings Strategy

Celltrion Offers 85% Discount For Adalimumab Biosimilar In US

Celltrion joins a number of other adalimumab competitors with dual pricing strategies as Humira biosimilars finally gain some traction in the US market.

United States Biosimilars

Corbus And Janux Lead Q1’s Small-Cap Winners

Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.

Commercial Clinical Trials

Clasp Launches With $150m To Develop Personalized T-Cell Engagers

Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.

Financing ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • InteKrin Therapeutics, Inc.
    • Coherus Intermediate Corp